Rising Thyroglobulin, — Negative Iodine Scan

Not necessarily, but it is the most common explanation after a total thyroidectomy and radioiodine ablation. A small amount of normal residual thyroid tissue can produce thyroglobulin, and thyroglobulin antibodies — which some patients develop — can interfere with the measurement and make the result harder to interpret. Your team will look at the trend over several visits and at antibody levels before concluding what the rise means. A single elevated reading is treated differently from a level that keeps climbing visit after visit.

There is no single number that reliably predicts a positive scan for every patient. What ATA guidance notes is that PET-CT detection rates improve as thyroglobulin rises — lower levels are harder to localise even when disease is present. Your oncologist will weigh your specific level, how fast it is rising, and what earlier imaging has shown when deciding whether the time for PET-CT has come. Asking this question directly at your next appointment is entirely reasonable.

A negative PET-CT alongside a rising thyroglobulin is an uncertain result, not a reassuring one. Disease may be present at a size or in a location the scan is less sensitive to — diffuse spread through the lungs is one recognised pattern that FDG-PET can underestimate. Your team may recommend repeating the scan after an interval, looking more closely at specific sites with neck ultrasound or chest CT, or continuing to monitor thyroglobulin with a plan to re-image if the level keeps rising.

It may indicate that, but it does not automatically mean it. Some patients have a mix of iodine-avid and non-iodine-avid disease, and further radioiodine may still be worthwhile where the iodine-avid component is clinically significant. The question of whether more radioiodine would help in your specific situation is one your oncologist will weigh against the risks of additional treatment. The negative scan result is important evidence in that decision, not a final ruling.

RAI stands for radioactive iodine. RAI-refractory means the cancer has become resistant to it — the cells no longer absorb enough iodine to be treated by it. ATA defines specific criteria for this, and a rising thyroglobulin with a negative iodine scan can meet those criteria. It is a clinical classification that matters because it guides which treatments are considered next, including systemic targeted therapies where indicated. Whether it applies to you is a question your oncologist can answer directly from your results.

A second opinion is always reasonable when results are complex or the proposed treatment is unfamiliar. Thyroid cancer that has dedifferentiated — losing iodine uptake — is a situation where a specialist centre experienced in RAI-refractory disease adds genuine value. Ask your current team to refer you, or ask specifically about their experience managing cases where radioiodine is no longer effective. A treating team confident in their assessment will not be troubled by the request, and it is your right to ask.